BioCentury
ARTICLE | Clinical News

CellSearch Circulating Tumor Cell Kit: Additional Phase III data

October 28, 2013 7:00 AM UTC

An analysis of 711 patients with metastatic castration-resistant prostate cancer (CRPC) in the double-blind, placebo-controlled, international Phase III COU-AA-301 trial of Zytiga abiraterone acetate showed that patients with >=5 CTCs as measured by Veridex LLC's CellSearch Circulating Tumor Cell Kit and lactate dehydrogenase (LDH) levels of >250 IU/L at 12 weeks of treatment had worse 1- (25% vs. 82%) and 2-year (2% vs. 46%) survival rates compared to patients with lower CTC counts and normal LDH levels. Data were presented at the European Cancer Congress in Amsterdam. Previously reported data from 841 patients with metastatic CRPC in the COU-AA-301 trial showed that CTC conversion was predictive of OS as early as 4 weeks after treatment. CTC conversion is defined as a change in CTC count from unfavorable (>=5 cells/7.5 mL) to favorable (<5 cells/7.5 mL) as measured by CellSearch (see BioCentury, June 13, 2011). ...